Citeline Introduces Global Patient Insights
15 mai 2024 09h00 HE
|
Citeline
Citeline announces the launch of Global Patient Insights, the industry’s most comprehensive view of the worldwide patient landscape.
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
15 mai 2024 08h05 HE
|
Third Harmonic Bio
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H’25 Strengthened leadership...
Global PIM Kinase Targeted Therapies Market Opportunity & Clinical Trials Report 2024: USA Dominating with 5 Therapies, FDA Orphan Designation, Proprietary Development Technologies by Companies
14 mai 2024 05h38 HE
|
Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Global PIM Kinase Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering....
Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance
13 mai 2024 08h00 HE
|
Science 37, Inc.
Science 37 Holdings, Inc. today announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation.
TrialWire Patient Recruitment Platform that Reboots Stalled Clinical Trials announced as Multi-Award Finalist in the 2024 Citeline Awards
12 mai 2024 16h29 HE
|
TrialWire
The TrialWire™ Rapid Patient Recruitment Platform, the only pay-per-enrolled fixed-fee solution powered by AI and algorithms, has been select for 3 awards
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
10 mai 2024 17h40 HE
|
Tevogen Bio Inc
$50 million in financing advances operational objectives and bolsters a financial path to positive cashflow with minimal dilution.
Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”
09 mai 2024 10h00 HE
|
Science 37, Inc.
Science 37 announces its selection as the winner of the “Clinical Efficiency Innovation Award” in the 8th annual MedTech Breakthrough Awards program.
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
08 mai 2024 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) --...
Fragile X Syndrome Global Clinical Trials Review 2024: Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
03 mai 2024 06h25 HE
|
Research and Markets
Dublin, May 03, 2024 (GLOBE NEWSWIRE) -- The "Fragile X Syndrome - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The analyst's clinical...
Global Graft Versus Host Disease (GVHD) Clinical Trials Review 2024
03 mai 2024 06h01 HE
|
Research and Markets
Dublin, May 03, 2024 (GLOBE NEWSWIRE) -- The "Graft Versus Host Disease (GVHD) - Global Clinical Trials Review, 2024" report has been added to ResearchAndMarkets.com's offering.This report will...